Paper Details

  1. Home
  2. Paper Details

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

Author: BerginC F, CourtneyM G, KeelingP W, NunesD P, O'DriscollM, TrimbleV, WeirD G

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Olsalazine was more effective than mesalazine in preventing relapses of ulcerative colitis, especially in patients with left-sided disease. Both drugs were well tolerated with only a small number of patients reporting side effects.
Paper Details　
Original Abstract of the Article :
Sulphasalazine extends remissions and lessens disease activity during relapses of ulcerative colitis, but it also causes many adverse side-effects. The adverse reactions are mostly attributable to the sulphapyridine carrier moiety rather than the active principle 5-aminosalicylic acid (5-ASA), so ag...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0140-6736(92)91601-4

データ提供：米国国立医学図書館（NLM）

Olsalazine vs. Mesalazine: A Comparative Study for Ulcerative Colitis

Ulcerative colitis, a chronic inflammatory bowel disease, often requires maintenance therapy to prevent relapses. Sulphasalazine, a traditional treatment, is effective but associated with side effects. This study compared the efficacy and tolerability of two newer agents, olsalazine and mesalazine, in preventing ulcerative colitis relapses. The researchers randomly assigned 100 patients in remission to receive either olsalazine or mesalazine for 12 months. They found that olsalazine significantly reduced the rate of treatment failure compared to mesalazine, particularly in patients with left-sided disease. Both drugs were well tolerated, with only a small number of patients experiencing substantial side effects.

Olsalazine: A Promising Option for Ulcerative Colitis Maintenance

This study highlights the potential of olsalazine as an effective and well-tolerated maintenance therapy for ulcerative colitis, especially in patients with left-sided disease. The findings suggest that olsalazine may provide a superior alternative to mesalazine in preventing relapses and improving long-term outcomes for patients.

Finding the Right Treatment: A Personal Journey

The search for the right treatment for ulcerative colitis is a personal journey, with each patient's experience being unique. This study provides valuable information for clinicians and patients, suggesting that olsalazine may offer a promising option for maintaining remission and improving quality of life for individuals with ulcerative colitis.

Dr.Camel's Conclusion

Navigating the sands of ulcerative colitis can be a challenging trek. This research presents olsalazine as a potential oasis, offering relief and stability for those seeking to maintain remission. While each patient's journey is unique, this study offers valuable insights for clinicians and patients alike, helping to guide them towards a more comfortable and fulfilling path.

Date :
  1. Date Completed 1992-06-11
  2. Date Revised 2019-06-10
Further Info :

Pubmed ID

1349676

DOI: Digital Object Identifier

10.1016/0140-6736(92)91601-4

Related Literature

Article Analysis
・Side Effects of olsalazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.